Loading clinical trials...

Evaluation of S-600918 in Adults With Refractory Chronic Cough | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Evaluation of S-600918 in Adults With Refractory Chronic Cough

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough

NCT04110054•Shionogi

View on ClinicalTrials.gov

Summary

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Having refractory chronic cough (including unexplained chronic cough) for at least 1 year.
•If female and of childbearing potential, agreement to use one of the allowed contraceptive methods.
•Capable of giving signed informed consent.

Exclusion Criteria

•Currently smokes or uses potentially irritating inhalational agents (eg, e-cigarettes, smokeless cigarettes, vaping); stopped smoking or using potentially irritating inhalational agents within the last year; or has a smoking history of 20 pack-years or more.
•Has chronic obstructive pulmonary disease or uncontrolled asthma.
•Has a clinically unstable medical condition.
•History of or ongoing significant psychiatric disorder.
•History of respiratory tract infection or significant change in lung function or a pulmonary condition in the last 4 weeks.
•History of malignancy in the last 5 years.
•History of severe drug allergy.
•History of alcohol or drug abuse in the last year or currently uses any form of marijuana or illicit drugs.
•Has a clinically significant finding on a chest x-ray or chest computed tomography (CT) scan in the last year.
•Has systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 90 mm Hg.
+5 more criteria

Locations (136)

Research Solutions of Arizona

Litchfield Park, Arizona, United States

Pulmonary Associates, PA

Phoenix, Arizona, United States

Alliance for Multispecialty Research

Tempe, Arizona, United States

Southern California Institute For Respiratory Diseases, Inc.

Los Angeles, California, United States

Allergy & Asthma Associates of Southern California dba Southern California Research

Mission Viejo, California, United States

California Medical Research Associates, Inc.

Northridge, California, United States

Center for Clinical Trials, LLC

Paramount, California, United States

Institute of HealthCare Assessment, Inc.

San Diego, California, United States

Sher Allergy Specialist/Center for Cough

Largo, Florida, United States

Medical Research Of Central Florida, LLC

Leesburg, Florida, United States

Key Dates

Start Date

February 13, 2020

Primary Completion Date

December 8, 2020

Completion Date

December 28, 2020

Last Updated

March 27, 2024

Enrollment

406

ACTUAL participants

Conditions

Chronic Cough

Interventions

S-600918

DRUG

Placebo to S-600918

DRUG

Analysis of the Reliability and Validity of the Chinese Version of CC-QoL

NCT05362097

Chronic Cough

View study

ACTIVE_NOT_RECRUITINGPHASE3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191

CoughRefractory Chronic Cough

View study

COMPLETEDPHASE2

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 27, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Inclusion Criteria

Exclusion Criteria

Analysis of the Reliability and Validity of the Chinese Version of CC-QoL

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

ATP Level and Cough Sensitivity to ATP in Subjects With Refractory/Unexplained Chronic Cough

Chronic Cough and Small Fiber Neuropathy

A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration